Home › Companies › CUE

Cue Biopharma

Market cap $23.7M 8.4M shares (10-Q, Nov 13, 2026) × $2.83 close Nov 17, 2026

Most recent annual filing: 2026-03-16

Catalyst timeline

4 trackedQuarter catalyst calendar →
  1. CUE-221 IND filing2H 2026CUE-221 IND filing, 2H 2026, material
  2. CUE-401 readout2H 2026/1H 2027CUE-401 readout, 2H 2026/1H 2027, material
  3. CUE-401 Ph1 startEnd of 2026CUE-401 Ph1 start, End of 2026, notable
  4. CUE-221 Ph2b start4Q 2026CUE-221 Ph2b start, 4Q 2026, notable

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (6 active programs)

Technology platforms

Immuno-STAT

Modular biologics platform designed to selectively engage and modulate disease-specific T cells for autoimmune, inflammatory, and oncology indications. Enables selective Treg induction/expansion, targeted cell depletion via anti-viral T cell redirection, and tumor-specific T cell activation.

Targets: TGF-β, IL-2, T cells, Tregs

Capital (as filed)

Cash
$57.9M cash and cash equivalents · Sep 30, 2026 (10-Q)
Operating cash flow
−$10.1M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$57.9M cash per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure

Offering documents (3)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (9)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (9 calls)

Every verdict Biotech Distilled has published on Cue Biopharma, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Cue Biopharma, Inc. (CUE) — Scientific Deep Dive for CUE-221 and Pipeline Products CUE-221 biology is real and the H2 2026 Phase 2 CSU readout is a legitimate binary catalyst, but the equity is a going-concern story with a punishing Ascendant change-of-control structure; track from the sidelines and re-evaluate after data.
  2. Speculative buy speculative UPDATE: Cue Biopharma (CUE) - The Horizon Crew Takes the Board The concentration of Horizon/AbbVie operators on a pruned five-person board is a real deal-prep signal that upgrades the team who will monetize the H2 2026 CSU binary, justifying a small speculative position.
  3. Speculative buy speculative UPDATE: Cue Biopharma (CUE) - The $50M Vote of Confidence and the CSU Clock Cormorant leading a $50M PIPE at $33.21 (3x the April mark) effectively neutralizes the going-concern risk and tightens the CSU readout to end of Q3 2026, maintaining the speculative buy with the binary now ~11 weeks out.
  4. Speculative buy speculative UPDATE: Cue Biopharma (CUE) - The CMO Chair Gets Filled, the PIPE Overhang Bites CMO hire completes the operator stack with 11 weeks to the binary, and the 15.9% pullback to near the institutional PIPE price offers a cleaner risk/reward without changing the fundamental setup.
  5. Speculative buy speculative UPDATE: Cue Biopharma (CUE) - The IND Nobody Noticed The food-allergy IND filing opens a US-controlled clinical path that partially answers the China-data-acceptance risk, while the CSU readout guidance holds at end-of-Q3 for a third consecutive disclosure.
  6. Speculative buy speculative UPDATE: Cue Biopharma (CUE) - A $153 Million Loss That Isn't a Loss The going-concern doubt is functionally resolved via the Q2 10-Q's twelve-month sufficiency assertion, Driehaus joins the institutional register, and the China manufacturing carve-out improves regulatory hygiene, but the science and the coin flip are unchanged with ~6 weeks to the binary.
  7. Speculative buy speculative UPDATE: Cue Biopharma (CUE) - The CEO's 13D and the 30% Air Pocket The 29.9% drawdown is driven by PSU settlement mechanics, a mandatory sell-to-cover, and a new S-3 shelf — cap-table plumbing, not clinical news — leaving the speculative buy intact with ~6 weeks to the binary.
  8. Buy core UPDATE: Cue Biopharma (CUE) - The Coin Landed, and It Landed Off-Drug The Phase 2 CSU binary resolved favorably with a clean dose-response, a 46% UAS7=0 at the top dose versus 11% placebo, and a 36-point off-drug gap at Week 28 that validates the CD23 mechanism, substantially retiring clinical risk while structural risks (FDA acceptance of China data, $215M Ascendant acceleration, dilution) remain.
  9. Speculative buy speculative UPDATE: Cue Biopharma (CUE) - Half the Price, a Green Light, and a Tax Bill FDA-cleared food-allergy IND and high-IgE subgroup data advance the science, but effective cash is ~$46M after a $12.1M payroll-tax accrual, the CSU regulatory path remains unresolved, and a 50% post-upgrade drawdown with no disclosed negative catalyst warrants cutting conviction one notch back to speculative.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (3 quotes from 3 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (32)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jul 9, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

25 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)